Elimination of cccDNA from infected cells
represents an attractive endpoint for HBV therapy,
but it may not be necessary for the cure of CHB. In
fact, individuals with resolved acute HBV infection
do not achieve complete viral eradication, but they
are able to control the virus indefinitely [20] without
any signs of liver damage. It may, therefore, be more
feasible to restore HBV-specific immunity to mimic
the immunological events that occur during acute
infection (Fig. 1b).